Skip to main content
SpringerLink
Log in

Evidence-based Anticancer Materia Medica for Bladder Cancer

  • Chapter
  • First Online:
Materia Medica for Various Cancers

Part of the book series: Evidence-based Anticancer Complementary and Alternative Medicine ((ACAM,volume 2))

  • 715 Accesses

Abstract

Bladder cancer is a relatively common urinary tract carcinoma. There are in general two categories of bladder cancer, low grade and high grade, which develop through distinct molecular pathways, have different clinical presentations and therefore require different management schemes. Regardless of tumor grade, most bladder cancers have high recurrence rate. Conventional treatments such as surgery, radiotherapy, and chemotherapy, though quite effective in managing the tumor burden itself, may not be effective enough to cure the disease. Herbal medicines, such as Zhuling, garlic, green tea, astragalus, triptolide, and Ganoderma lucidum, provide potential alternatives for the management of this disease. This chapter provides an overview of the scientific research studying the efficacy and potential mechanisms of action of these herbal remedies in the treatment of bladder cancer. Some of the active ingredients in the herbs have been shown to be effective in inhibiting tumor growth in vitro and in vivo. Animal models and cell line studies provide experimental evidence demonstrating the potential therapeutic effects of these herbs. Obviously, definitive clinical trials are needed to evaluate the safety and efficacy of herbal ­management of bladder cancer. In this chapter, we also discuss the relationship of nutrition and diet with bladder cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Aben KK, Kiemeney LA (1999) Epidemiology of bladder cancer. Eur Urol 36:660–672

    Article  PubMed  Google Scholar 

  • Amaral AF, Cantor KP, Silverman DT, Malats N (2010) Selenium and bladder cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev 19:2407–2415

    Article  PubMed  CAS  Google Scholar 

  • Bakkar AA, Wallerand H, Radvanyi F et al (2003) FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder. Cancer Res 63:8108–8112

    PubMed  CAS  Google Scholar 

  • Bane BL, Rao J, Hemstreet GP (1996) Pathology and staging of bladder cancer. Semin Oncol Bladder Cancer 23:546–570

    CAS  Google Scholar 

  • Billerey C, Chopin D, Aubriot-Lorton MH et al (2001) Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am J Pathol 158:1955–1959

    Article  PubMed  CAS  Google Scholar 

  • Bjurlin MA, Goble SM, Hollowell CM (2010) Smoking cessation assistance for patients with bladder cancer: a national survey of American urologists. J Urol 184:1901–1906

    Article  PubMed  Google Scholar 

  • Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R (2003) The health economics of ­bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics 21:1315–1330

    Article  PubMed  Google Scholar 

  • Brinkman MT, Karagas MR, Zens MS, Schned A, Reulen RC, Zeegers MP (2010) Minerals and vitamins and the risk of bladder cancer: results from the New Hampshire study. Cancer Causes Control 21:609–619

    Article  PubMed  Google Scholar 

  • Cassidy A, Wang W, Lin J (2009) Risk of urinary bladder cancer: a case-control analysis of industry and occupation. BMC Cancer 9:443

    Article  PubMed  Google Scholar 

  • Cheng L, Zhang S, MacLennan GT, Williamson SR, Lopez-Beltran A, Montironi R (2011) Bladder cancer: translating molecular genetic insights into clinical practice. Human Pathol 42:455–481.

    Google Scholar 

  • Cheung E, Quinn D, Tsao-Wei D, Groshen SG Aparicio A, Twardowski P et al (2008) Phase II study of vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in patients with advanced transitional cell urothelial cancer (TCC) after platinum-based therapy. California Cancer Consortium/University of Pittsburgh NCI/CTEP sponsored trial. J Clin Oncol 26:abstract 16058

    Google Scholar 

  • Chow N, Chan S, Tzai T, Ho C, Liu H (2001) Expression profiles of ErbB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder. Clin Cancer Res 7:1957–1962

    PubMed  CAS  Google Scholar 

  • Dreicer R, Li H, Stein MN, DiPaola RP, Eleff M, Roth BJ et al (2008) Phase II trial of sorafenib in advanced carcinoma of the urothelium: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 26:abstract 5083

    Google Scholar 

  • Feldman A, Kirley S, McDougal WS, Zukerberg LR, Wu CL (2003) Expression of cables, a cell cycle regulatory gene is lost in human prostate cancer and suppresses prostate cancer cell growth. J Urol 169:188 (American Urological Association, Abstract 727)

    Google Scholar 

  • Gallagher D, Milowsky M, Gerst S, Iasonos A, Boyle M, Trout A et al (2008) Final results of a phase ii study of sunitinib in patients with relapsed or refractory urothelial carcinoma. J Clin Oncol 26:abstract 5082

    Google Scholar 

  • Gloeckler Ries L, Reichman M, Lewis D, Hankey B, Edwards B (2003) Cancer survival and incidence from the Surveillance, Epidemiology, and End Results (SEER) program. Oncologist 8:541–552

    Article  PubMed  Google Scholar 

  • Habuchi T, Marberger M, Droller MJ, Hemstreet GP 3rd, Grossman HB, Schalken JA et al (2005) Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers. Urology 66:64–74

    Article  PubMed  Google Scholar 

  • Hernandez L, Wu X, Lin J, Radcliffe J (2004) Intake of vitamin E (2-R isomers of alpha-tocopherol) and gamma-tocopherol in a case-control study and bladder cancer risk. Proc Am Assoc Cancer Res 45:abstract #3921

    Google Scholar 

  • Hirao Y, Kim WJ, Fujimoto K (2009) Environmental factors promoting bladder cancer. Curr Opin Urol 19:494–499

    Article  PubMed  Google Scholar 

  • Jaye M, Schlessinger J, Dionne CA (1992) Fibroblast growth factor receptor tyrosine kinases: molecular analysis and signal transduction. Biochim Biophys Acta 1135:185–199

    Article  PubMed  CAS  Google Scholar 

  • Jemal A, Siegal R, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60:277–300

    Article  PubMed  Google Scholar 

  • Junttila T, Laato M, Vahlberg T, Söderström K, Visakorpi T, Isola J et al (2003) Identification of patients with transitional cell carcinoma of the bladder overexpressing ErbB2, ErbB3, or specific ErbB4 isoforms: real-time reverse transcription-PCR analysis in estimation of ErbB receptor status from cancer patients. Clin Cancer Res 9:5346–5357

    PubMed  CAS  Google Scholar 

  • Kohlmeier L, Weterings KG, Steck S, Kok FJ (1997) Tea and cancer prevention: an evaluation of the epidemiologic literature. Nutr Cancer 27:1–13

    Article  PubMed  CAS  Google Scholar 

  • Kurashige S, Akuzawa Y, Endo F (1999) Effects of astragali radix extract on carcinogenesis, cytokine production, and cytotoxicity in mice treated with a carcinogen, N-butyl-N’-butanolnitrosoamine. Cancer Invest 17:30–35

    PubMed  CAS  Google Scholar 

  • Lamm D, Riggs D (2000) The potential application of Allium sativum (garlic) for the treatment of bladder cancer. Urol Clin North Am 27:157–162

    Article  PubMed  CAS  Google Scholar 

  • Lau BHS, Woolley JL, Marsh CL et al (1986) Superiority of intralesional immunotherapy with Corynebacterium parvum and Allium sativum in control of murine transitional cell carcinoma. J Urol 136:701–705

    PubMed  CAS  Google Scholar 

  • Lu QY, Jin YS, Zhang Q, Zhang ZF, Heber D, Go VL et al (2004) Ganoderma lucidum extracts inhibit growth and induce actin polymerization in bladder cancer cells in vitro. Cancer Lett 216:9–20

    Article  PubMed  CAS  Google Scholar 

  • Lu QY, Jin YS, Pantuck A, Zhang ZF, Heber D, Belldegrun A (2005) Green tea extract modulates actin remodeling via Rho activity in an in vitro multistep carcinogenic model. Clin Cancer Res 11:1675–1683

    Article  PubMed  CAS  Google Scholar 

  • MD Anderson Cancer Center web site: Bladder cancer. http://www.mdanderson.org/patient-and-cancer-information/cancer-information/cancer-types/bladder-cancer/index.html. Accessed 12 Sep 2011

  • Mhawech-Fauceglia P, Cheney RT, Schwaller J (2006) Genetic alterations in urothelial bladder carcinoma: an updated review. Cancer 106:1205–1216

    Article  PubMed  CAS  Google Scholar 

  • Michaud DS, Spiegelman D, Clinton SK, Rimm EB, Curhan GC, Willett WC (1999) Fluid intake and the risk of bladder cancer in men. N Engl J Med 340:1390–1397

    Article  PubMed  CAS  Google Scholar 

  • Mondul A, Weinstein S, Männistö S, Snyder K, Horst R, Virtamo J et al (2010) Serum vitamin D and risk of bladder cancer. Cancer Res 70:9218–9223

    Article  PubMed  CAS  Google Scholar 

  • Mueller C, Caporaso N, Greene M (2008) Familial and genetic risk of transitional cell carcinoma of the urinary tract. Urol Oncol 26:451–464

    Article  PubMed  CAS  Google Scholar 

  • Naito S, Tanaka K, Koga H, Kotoh S, Hirohata T, Kumazawa J (1995) Cancer occurrence among dyestuff workers exposed to aromatic amines. A long term follow-up study. Cancer 76:1445–1452

    Article  PubMed  CAS  Google Scholar 

  • NCI/NIH. Bladder cancer. http://www.cancer.gov/cancertopics/types/bladder. Accessed 12 Sep 2011

  • Primdahl H, von der Maase H, Sørensen FB, Wolf H, Ørntoft T (2002) Immunohistochemical study of the expression of cell cycle regulating proteins at different stages of bladder cancer. J Cancer Res Clin Oncol 128:295–301

    Article  PubMed  CAS  Google Scholar 

  • Radosavljević V, Janković S, Marinković J, Dokić M (2005) Diet and bladder cancer: a case-control study. Int Urol Nephrol 37:283–289

    Article  PubMed  Google Scholar 

  • Santos L, Amaro T, Pereira SA, Lameiras CR, Lopes P, Bento M et al (2003) Expression of cell-cycle regulatory proteins and their prognostic value in superficial low-grade urothelial cell carcinoma of the bladder. Eur J Surg Oncol 29:74–80

    Article  PubMed  CAS  Google Scholar 

  • Sato D (1999) Inhibition of urinary bladder tumors induced by N-butyl-N-(4 -hydroxybutyl)-nitrosamine in rats by green tea. Int J Urol 6:93–99

    Article  PubMed  CAS  Google Scholar 

  • Scosyrev E, Noyes K, Feng C, Messing E (2009) Sex and racial differences in bladder cancer presentation and mortality in the US. Cancer 115:68–74

    Article  PubMed  Google Scholar 

  • Sgambato A, Migaldi M, Faraglia B, De Aloysio G, Ferrari P, Ardito R et al (2002) Cyclin D1 expression in papillary superficial bladder cancer: its association with other cell cycle-associated proteins, cell proliferation and clinical outcome. Int J Cancer 97:671–678

    Article  PubMed  CAS  Google Scholar 

  • Shinohara N, Koyanagi T (2002) Ras signal transduction in carcinogenesis and progression of bladder cancer: molecular target for treatment? Urol Res 30:273–281

    Article  PubMed  CAS  Google Scholar 

  • Urist M, Di Como C, Lu M, Charytonowicz E, Verbel D, Crum CP et al (2002) Loss of p63 expression is associated with tumor progression in bladder cancer. Am J Pathol 161:1199–1206

    Article  PubMed  CAS  Google Scholar 

  • van Rhijn B, van der Kwast T, Vis A et al (2004) FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma. Cancer Res 64:1911–1914

    Article  PubMed  Google Scholar 

  • Vecchione A, Sevignani C, Giarnieri E, Zanesi N, Ishii H, Cesari R et al (2004) Inactivation of the FHIT gene favors bladder cancer development. Clin Cancer Res 10:7607–7612

    Article  PubMed  CAS  Google Scholar 

  • Yang D (1991) Inhibitory effect of Chinese herb medicine zhuling on urinary bladder cancer. An experimental and clinical study. Zhonghua Wai Ke Za Zhi 29:393–395, 399

    Google Scholar 

  • Yang D, Li S, Wang H, Li X, Liu S, Han W et al (1999) Prevention of postoperative recurrence of bladder cancer: a clinical study. Zhonghua Wai Ke Za Zhi 37:464–465

    PubMed  CAS  Google Scholar 

  • Yang C, Wang X, Lu G, Picinich S (2009) Cancer prevention by tea: animal studies, molecular mechanisms and human relevance. Nat Rev Cancer 9:429–439

    Article  PubMed  CAS  Google Scholar 

  • Yang S, Chen J, Guo Z, Xu XM, Wang L, Pei XF et al (2003) Triptolide inhibits the growth and metastasis of solid tumors. Mol Cancer Ther 2:65–72

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA, 90095-1732, USA

    Dawei Ye, Hongyu Zhao, Michelle Chow & Jianyu Rao

  2. Department of Epidemiology, School of Public Health, University of California, Los Angeles, CA, 90095, USA

    Pingping Gu

  3. Department of Oncology, Ganzhou City People’s Hospital, Jiangxi, 341000, PR China

    Xiaoqing Guo

Authors
  1. Dawei Ye
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pingping Gu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hongyu Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Michelle Chow
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Xiaoqing Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jianyu Rao
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jianyu Rao .

Editor information

Editors and Affiliations

  1. Queen Elizabeth Hospital, Department of Clinical Oncology, Room 1305, 13/F, Block R, Gascoigne Road 30, Kowloon, Hong Kong, China, People's Republic

    William C.S. Cho

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media B.V.

About this chapter

Cite this chapter

Ye, D., Gu, P., Zhao, H., Chow, M., Guo, X., Rao, J. (2012). Evidence-based Anticancer Materia Medica for Bladder Cancer. In: Cho, W. (eds) Materia Medica for Various Cancers. Evidence-based Anticancer Complementary and Alternative Medicine, vol 2. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-1983-5_10

Download citation

Publish with us

Policies and ethics

Search

Navigation